09 April 2024: Original Paper
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study
Atif S. Siddiqui 12ABCDEF* , Jawairia Shakil 23CDEFDOI: 10.12659/AOT.943652
Ann Transplant 2024; 29:e943652
Table 3 Characteristics associated with the occurrence of composite events – univariable logistic regression.
| No composite event | Composite event* | Univariable | Multivariable | |||
|---|---|---|---|---|---|---|
| (n=74) | (n=158) | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| 42 (56.8) | 116 (73.4) | 2.10 (1.18, 3.76) | 0.01 | 1.71 (0.86, 3.42) | 0.13 | |
| Age at transplant (years), median (IQR) | 63.0 (58.0, 66.6) | 61.2 (52.5, 65.9) | 0.97 (0.94, 1.00) | 0.04 | 0.99 (0.95, 1.03) | 0.51 |
| Male gender | 42 (56.8) | 85 (53.8) | 0.89 (0.51, 1.55) | 0.67 | -- | -- |
| Ethnicity | ||||||
| White | 58 (78.4) | 94 (59.5) | (reference) | -- | -- | |
| Black6 | 8 (10.8) | 36 (22.8) | 2.78 (1.21, 6.39) | 0.02 | -- | -- |
| Hispanic/Latino | 6 (8.1) | 22 (13.9) | 2.26 (0.87, 5.91) | 0.10 | -- | -- |
| Asian | 2 (2.7) | 6 (3.8) | 1.85 (0.36, 9.48) | 0.46 | -- | -- |
| Non-White | 16 (21.6) | 64 (40.5) | 2.47 (1.30, 4.67) | 0.01 | 2.26 (1.10, 4.64) | 0.03 |
| Body mass index at transplant, median (IQR) | 28.6 (22.5, 31.5) | 26.6 (23.4, 30.4) | 0.98 (0.92, 1.03) | 0.40 | -- | -- |
| Double lung transplant | 47 (63.5) | 124 (78.5) | 2.10 (1.14, 3.84) | 0.02 | 1.16 (0.53, 2.52) | 0.71 |
| Primary diagnosis | ||||||
| Chronic obstructive pulmonary disease (COPD) | 17 (23.0) | 35 (22.2) | (reference) | |||
| Cystic fibrosis | 2 (2.7) | 7 (4.4) | 1.70 (0.32, 9.07) | 0.54 | 1.28 (0.61, 2.71) | 0.51 |
| Interstitial lung disease (ILD) | 49 (66.2) | 97 (61.4) | 0.96 (0.49, 1.89) | 0.91 | 1.14 (0.16, 8.08) | 0.90 |
| Other | 6 (8.1) | 19 (12.0) | 1.54 (0.52, 4.55) | 0.44 | 1.37 (0.48, 3.91) | 0.56 |
| Previous malignancy | 5 (6.8) | 8 (5.1) | 0.74 (0.23, 2.33) | 0.60 | -- | -- |
| Diabetes | 21 (28.4) | 47 (29.7) | 1.07 (0.58, 1.97) | 0.83 | -- | -- |
| History of smoking | 46 (62.2) | 88 (55.7) | 0.77 (0.43, 1.35) | 0.35 | -- | -- |
| Months in wait list, median (IQR) | 1.8 (0.8, 5.3) | 1.7 (0.5, 3.8) | 0.99 (0.95, 1.04) | 0.74 | -- | -- |
| Total serum bilirubin (mg/dL), median (IQR) | 0.3 (0.2, 0.5) | 0.3 (0.2, 0.5) | 1.13 (0.40, 3.21) | 0.81 | -- | -- |
| Serum creatinine at transplant, median (IQR) | 0.8 (0.7, 1.0) | 0.8 (0.7, 1.0) | 1.05 (0.68, 1.64) | 0.82 | -- | -- |
| eGFR at transplant (mL/mn/1.73 m), median (IQR) | 90.4 (73.9, 99.0) | 92.4 (76.0, 103.3) | 1.01 (1.00, 1.02) | 0.22 | -- | -- |
| eGFR at transplant | 10 (13.5) | 15 (9.5) | 0.67 (0.29, 1.57) | 0.36 | -- | -- |
| Pre-transplant ventilation | 2 (2.7) | 7 (4.4) | 1.67 (0.34, 8.24) | 0.53 | -- | -- |
| Systolic PA pressure at transplant (mmHg), median (IQR) | 35.0 (29.0, 42.0) | 38.0 (32.0, 50.0) | 1.01 (0.99, 1.03) | 0.26 | -- | -- |
| Diastolic PA pressure at transplant (mmHg), median (IQR) | 15.0 (11.0, 20.0) | 17.0 (12.0, 21.0) | 1.02 (0.99, 1.06) | 0.21 | -- | -- |
| Mean PA pressure at transplant (mmHg), median (IQR) | 22.0 (16.0, 28.0) | 24.0 (18.5, 30.0) | 1.01 (0.99, 1.04) | 0.39 | -- | -- |
| Mean PCWP (mmHg), median (IQR) | 9.0 (6.0, 12.0) | 10.0 (6.0, 14.0) | 1.04 (0.98, 1.10) | 0.23 | -- | -- |
| Hemoglobin level pre lung transplant (g/dL), median (IQR) | 12.1 (11.0, 13.6) | 12.0 (10.5, 13.1) | 0.90 (0.77, 1.05) | 0.17 | 0.97 (0.81, 1.16) | 0.72 |
| Platelet count pre lung transplant (k/microliter), median (IQR) | 240.5 (197.0, 289.0) | 240.0 (198.0, 283.0) | 1.00 (0.99, 1.00) | 0.43 | -- | -- |
| INR pre-transplant, median (IQR) | 1.0 (1.0, 1.0) | 1.0 (1.0, 1.0) | 6.68 (0.91, 49.25) | 0.06 | -- | -- |
| Lowest PO2/FIO2 ratio, POD 0, median (IQR) | 263.5 (190.0, 400.0) | 216.3 (125.0, 335.0) | 1.00 (1.00, 1.00) | 0.09 | -- | -- |
| Extended spectrum β-lactamase (ESBL) (mL), median (IQR) | 1000.0 (500.0, 1500.0) | 1000.0 (750.0, 1750.0) | 1.00 (1.00, 1.00) | 0.07 | -- | -- |
| Intraoperative cell saver (mL), median (IQR) | 472.0 (225.0, 850.0) | 500.0 (281.0, 785.0) | 1.00 (1.00, 1.00) | 0.32 | -- | -- |
| Recipient CMV | 49 (66.2) | 114 (72.2) | 1.32 (0.73, 2.39) | 0.36 | -- | -- |
| CMV high risk (D+/R−) | 21 (28.4) | 31 (19.6) | 0.62 (0.32, 1.17) | 0.14 | -- | -- |
| HLA mismatch, median (IQR) | 5.0 (4.0, 5.0) | 5.0 (4.0, 6.0) | 1.10 (0.83, 1.46) | 0.50 | -- | -- |
| HLA mismatch ≥5 | 46 (64.8) | 99 (63.9) | 0.96 (0.53, 1.73) | 0.89 | -- | -- |
| Donor age (years), median (IQR) | 32.0 (25.0, 44.0) | 30.0 (21.0, 40.0) | 0.99 (0.96, 1.01) | 0.22 | -- | -- |
| Donor male gender | 33 (44.6) | 93 (58.9) | 1.78 (1.02, 3.10) | 0.04 | 2.06 (1.13, 3.77) | 0.02 |
| Donor race/ethnicity | ||||||
| White | 26 (35.1) | 75 (47.5) | (reference) | -- | -- | |
| Black | 21 (28.4) | 32 (20.3) | 0.53 (0.26, 1.07) | 0.08 | -- | -- |
| Hispanic | 24 (32.4) | 46 (29.1) | 0.66 (0.34, 1.29) | 0.23 | -- | -- |
| Asian | 3 (4.1) | 4 (2.5) | 0.46 (0.10, 2.20) | 0.33 | -- | -- |
| Other | 0 (0.0) | 1 (0.6) | NA | -- | -- | |
| Donor body mass index, median (IQR) | 26.5 (23.5, 31.2) | 25.7 (22.5, 30.0) | 0.98 (0.94, 1.03) | 0.46 | -- | -- |
| Donor history of hypertension | 15 (20.3) | 40 (25.3) | 1.33 (0.68, 2.61) | 0.40 | -- | -- |
| Donor history of diabetes | 4 (5.4) | 15 (9.5) | 1.84 (0.59, 5.74) | 0.30 | -- | -- |
| Donor history of smoking | 2 (2.8) | 10 (6.5) | 2.41 (0.52, 11.31) | 0.26 | -- | -- |
| Ischemic time (hours), median (IQR) | 4.0 (3.3, 4.9) | 4.2 (3.3, 4.8) | 1.11 (0.88, 1.39) | 0.38 | -- | -- |
| Donor-recipient concordance | 41 (55.4) | 90 (57.0) | 1.07 (0.61, 1.86) | 0.82 | -- | -- |
| Donor-recipient gender | ||||||
| Female-Female | 20 (27.0) | 35 (22.2) | (reference) | -- | -- | |
| Female-Male | 21 (28.4) | 30 (19.0) | 1.23 (0.56, 2.68) | 0.61 | -- | -- |
| Male-Female | 12 (16.2) | 38 (24.1) | 2.22 (0.94, 5.22) | 0.07 | -- | -- |
| Male-Male | 21 (28.4) | 55 (34.8) | 1.83 (0.87, 3.88) | 0.11 | -- | -- |
| Values are in number and% unless otherwise specified; IQR, interquartile range. * Composite outcome within 30 days of either mortality, acute myocardial infarction, acute stroke, lower respiratory ction, urinary tract tra infection, surgical site Infections, or primary graft dysfunction. OR – odds ratio; CI – confidence interval; AUC – area under the ROC curve. | ||||||